Not Just Drug Demand
$Eli Lilly(LLY)$’s August 5 report arrives with little doubt that demand for its diabetes and obesity medicines is strong. The harder question is whether production, pricing and access can turn that demand into sustainable earnings at a valuation that already anticipates exceptional growth.
Lilly reported its first quarter on April 30. Revenue increased 56% year over year to $19.8 billion, primarily because of higher Mounjaro and Zepbound volume, partly offset by lower realised prices. Key-product revenue reached $13.4 billion, and reported earnings increased 170% to $8.26 per share.
Mounjaro and Zepbound together represented 65% of quarterly revenue, demonstrating both extraordinary momentum and material concentration. Lilly’s first-quarter results and first-quarter Form 10-Q provide the financial and concentration data.
The bullish thesis combines expanding treatment demand, broader insurance access and a pipeline that could extend Lilly’s leadership. Manufacturing expansion is central to that opportunity. On May 6, Lilly committed another $4.5 billion across Indiana sites, bringing its capital commitments in the state since 2020 to $21 billion. On July 30, Lilly and contract manufacturer Resilience announced a further $750 million US capacity investment. Lilly’s Indiana manufacturing announcement and Reuters’ report on the Resilience agreement document those events.
The risks are concentration, competition and price. Greater public and private insurance access can increase volume but also reduce the price realised per prescription. Rival medicines, adverse clinical or regulatory developments and slower factory ramp-ups could alter expectations quickly. At $1,148.84 on July 31, Lilly traded at roughly 41 times trailing earnings, so very strong growth must persist to defend the multiple.
Friday’s range was wide: $1,120.12 to $1,162.51. The close held at $1,148.84, making approximately $1,120 initial support and $1,160–$1,165 immediate resistance. A break in either direction would be more meaningful if accompanied by a change in product guidance rather than price alone.
LLY’s weekly chart remains structurally bullish, but with earnings due 5 August before the market opens, the near-term direction is unusually binary and the stock could gap sharply in either direction.
Price is currently testing the prior Fibonacci breakout area around $1,134, which is the first level bulls need to defend; holding above this zone would preserve the possibility of another advance toward the recent $1,200–$1,230 highs and subsequently the 1.272 Fibonacci extension near $1,273, while a decisive breakdown could trigger a deeper retracement toward roughly $1,050–$1,100 and eventually the stronger $850–$907 support zone.
Given the earnings risk, I would avoid selling an aggressive near-the-money put and instead consider a 30–45 DTE cash-secured put around the $850 strike, ideally only if its delta is around 0.05–0.10 and the elevated pre-earnings premium provides an attractive return on secured cash; this places the strike roughly 25% below the current price and near substantial technical support, while benefiting from both time decay and the likely post-earnings volatility contraction. The trade should only be taken if assignment at an effective cost below $850 would be acceptable, because an earnings gap can overwhelm even a low-delta option. [Warning]
The evidence leans bullish because demand, earnings and capacity investment reinforce one another. The view would be invalidated by Mounjaro or Zepbound growth slowing sharply, realised-price pressure overwhelming volume, production delays or pipeline setbacks increasing dependence on the two leading products. This is personal opinion for education and is not financial advice.
@Tiger_SG @Tiger_comments @TigerStars @TigerClub @CaptainTiger @Daily_Discussion
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The views expressed are personal opinions based on publicly available information and are subject to change without notice. Investors should conduct their own research and consider their financial situation, risk tolerance, and investment objectives before making any investment decisions. I do not guarantee the accuracy or completeness of the information presented.
Comments